Aileron Therapeutics Inc. filed for an IPO of up to $69.0 million of its common stock.
The company plans to apply for listing of common stock on the Nasdaq Global Market under the symbol ALRN.
Aileron plans to use the net proceeds from the offering to fund ongoing clinical trials of ALRN-6924, to fund additional research and clinical development activity related to ALRN-6924 and other programs, and for working capital and other general corporate purposes.
Merrill Lynch Pierce Fenner & Smith Inc., Jefferies LLC, William Blair & Co. LLC and Canaccord Genuity Inc. are acting as underwriters in the offering.
Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of therapeutics called stapled peptides.